Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment

Li Zhang, Jeffrey S. Davis, Stanislav Zelivianski, Fen Fen Lin, Rachel Schutte, Thomas L. Davis, Ralph Hauke, Surinder Kumar Batra, Ming-Fong Lin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to members of the ErbB-ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells. Under an androgen-reduced condition, 50 nM gemcitabine caused about 40% growth suppression on C-81 cells. Simultaneous treatment of gemcitabine plus 10 μM AG825 produced 60% suppression (p < 0.03); while, 85% growth inhibition (p < 0.02) was seen if AG825 was added to gemcitabine-treated cells after a 24 h-interval. Our data thus showed that in androgen-reduced conditions, inhibition of ErbB-2 increases the cytotoxic efficacy of gemcitabine in PCa cells. This finding has significant implications in the choice of drugs for combination therapy as well as the order of administration for treating cancer patients.

Original languageEnglish (US)
Pages (from-to)58-65
Number of pages8
JournalCancer Letters
Volume285
Issue number1
DOIs
StatePublished - Nov 18 2009

Fingerprint

gemcitabine
Androgens
Prostatic Neoplasms
MAP Kinase Signaling System
Growth
Combination Drug Therapy
Signal Transduction
Pharmaceutical Preparations
Neoplasms

Keywords

  • Combination therapy
  • ErbB-2 inhibitor
  • Gemcitabine
  • Hormone-refractory prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment. / Zhang, Li; Davis, Jeffrey S.; Zelivianski, Stanislav; Lin, Fen Fen; Schutte, Rachel; Davis, Thomas L.; Hauke, Ralph; Batra, Surinder Kumar; Lin, Ming-Fong.

In: Cancer Letters, Vol. 285, No. 1, 18.11.2009, p. 58-65.

Research output: Contribution to journalArticle

Zhang, Li ; Davis, Jeffrey S. ; Zelivianski, Stanislav ; Lin, Fen Fen ; Schutte, Rachel ; Davis, Thomas L. ; Hauke, Ralph ; Batra, Surinder Kumar ; Lin, Ming-Fong. / Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment. In: Cancer Letters. 2009 ; Vol. 285, No. 1. pp. 58-65.
@article{bbe2c0bb064543ea8fc3de4b8162de35,
title = "Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment",
abstract = "We examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to members of the ErbB-ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells. Under an androgen-reduced condition, 50 nM gemcitabine caused about 40{\%} growth suppression on C-81 cells. Simultaneous treatment of gemcitabine plus 10 μM AG825 produced 60{\%} suppression (p < 0.03); while, 85{\%} growth inhibition (p < 0.02) was seen if AG825 was added to gemcitabine-treated cells after a 24 h-interval. Our data thus showed that in androgen-reduced conditions, inhibition of ErbB-2 increases the cytotoxic efficacy of gemcitabine in PCa cells. This finding has significant implications in the choice of drugs for combination therapy as well as the order of administration for treating cancer patients.",
keywords = "Combination therapy, ErbB-2 inhibitor, Gemcitabine, Hormone-refractory prostate cancer",
author = "Li Zhang and Davis, {Jeffrey S.} and Stanislav Zelivianski and Lin, {Fen Fen} and Rachel Schutte and Davis, {Thomas L.} and Ralph Hauke and Batra, {Surinder Kumar} and Ming-Fong Lin",
year = "2009",
month = "11",
day = "18",
doi = "10.1016/j.canlet.2009.04.041",
language = "English (US)",
volume = "285",
pages = "58--65",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment

AU - Zhang, Li

AU - Davis, Jeffrey S.

AU - Zelivianski, Stanislav

AU - Lin, Fen Fen

AU - Schutte, Rachel

AU - Davis, Thomas L.

AU - Hauke, Ralph

AU - Batra, Surinder Kumar

AU - Lin, Ming-Fong

PY - 2009/11/18

Y1 - 2009/11/18

N2 - We examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to members of the ErbB-ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells. Under an androgen-reduced condition, 50 nM gemcitabine caused about 40% growth suppression on C-81 cells. Simultaneous treatment of gemcitabine plus 10 μM AG825 produced 60% suppression (p < 0.03); while, 85% growth inhibition (p < 0.02) was seen if AG825 was added to gemcitabine-treated cells after a 24 h-interval. Our data thus showed that in androgen-reduced conditions, inhibition of ErbB-2 increases the cytotoxic efficacy of gemcitabine in PCa cells. This finding has significant implications in the choice of drugs for combination therapy as well as the order of administration for treating cancer patients.

AB - We examined the efficacy of combination treatments utilizing cytotoxic drugs plus inhibitors to members of the ErbB-ERK signal pathway in human prostate cancer (PCa) LNCaP C-81 cells. Under an androgen-reduced condition, 50 nM gemcitabine caused about 40% growth suppression on C-81 cells. Simultaneous treatment of gemcitabine plus 10 μM AG825 produced 60% suppression (p < 0.03); while, 85% growth inhibition (p < 0.02) was seen if AG825 was added to gemcitabine-treated cells after a 24 h-interval. Our data thus showed that in androgen-reduced conditions, inhibition of ErbB-2 increases the cytotoxic efficacy of gemcitabine in PCa cells. This finding has significant implications in the choice of drugs for combination therapy as well as the order of administration for treating cancer patients.

KW - Combination therapy

KW - ErbB-2 inhibitor

KW - Gemcitabine

KW - Hormone-refractory prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=70349270611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349270611&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2009.04.041

DO - 10.1016/j.canlet.2009.04.041

M3 - Article

C2 - 19467571

AN - SCOPUS:70349270611

VL - 285

SP - 58

EP - 65

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -